Combination of Pertuzumab and Erlotinib as 2nd-/3rd-Line (2/3L) Treatment for Patients (pts) With Metastatic Non-Small Cell Lung Cancer (NSCLC) - Safety and Anti-Tumour Activity by FDG-PET/CT Imaging Changes

被引：0
|
作者：
Hughes, B. [1 ]
Mileshkin, L. [2 ]
Townley, P. [3 ]
Gitlitz, B. [4 ]
Eaton, K. [5 ]
Mitchell, P. [6 ]
Hicks, R. [2 ]
Loecke, D. [7 ]
Amler, L. [7 ]
Pirzkall, A. [7 ]
机构：
[1] Royal Brisbane & Womens Hosp, Canc Care Serv, Brisbane, Qld, Australia
[2] Peter MacCallum Canc Ctr, Div Haematol & Med Oncol, Melbourne, Vic, Australia
[3] Nebraska Canc Specialists, Methodist Estabrook Canc Ctr, Omaha, NE USA
[4] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[5] Univ Washington, Med Ctr, Dept Internal Med, Seattle, WA 98195 USA
[6] Austin Hosp, Ludwig Med Oncol Dept, Melbourne, Vic 3084, Australia
[7] Genentech Inc, BioOncol, San Francisco, CA 94080 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)72431-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S629 / S629
页数：1
相关论文
共 50 条
  • [1] Current practices in 1st-(1L), 2nd-(2L), and 3rd-line (3L) treatment for metastatic colorectal cancer (mCRC).
    Thompson, Stephen F.
    Iqbal, Sheikh Usman
    Naoshy, Sarah
    Ng, Daniel B.
    Andria, Michael L.
    Sherman, Steven A.
    Malangone, Elisabetta
    Stern, Lee
    Gorritz-Kindu, Magdaliz
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Phase I study of gefitinib in combination with FOLFIRI as 2nd-/3rd-line treatment in patients with metastatic colorectal cancer.
    Hochhaus, A
    Hofheinz, R
    Heike, M
    Schlag, R
    Gahlemann, CG
    Kubicka, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 289S - 289S
  • [3] Use of erlotinib in patients selected using clinical criteria in the 2nd and 3rd line treatment of non-small cell lung cancer (NSCLC)
    Stavridi, F.
    Eestila, S.
    Merchant, S.
    Cane, P.
    Spicer, J.
    LUNG CANCER, 2009, 63 : S5 - S5
  • [4] Randomized Study of Pralatrexate vs Erlotinib in 2nd-and 3rd-Line Advanced Non-Small Cell Lung Cancer (NSCLC): Results in Subgroups and Factors Affecting Outcome
    Kelly, K.
    Azzoli, C. G.
    Weems, G.
    Koutsoukos, T.
    Zatloukal, P.
    Patel, J. D.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S559 - S559
  • [5] Changes in FDG- and FLT-PET imaging in patients with non-small cell lung cancer (NSCLC) following treatment with erlotinib (E)
    Mileshkin, L. R.
    Hughes, B. G.
    Mitchell, P.
    Charu, V.
    Gitlitz, B. J.
    Macfarlane, D.
    Yu, W.
    Pirzkall, A.
    Hicks, R.
    Fine, B. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Adverse effects and associated costs with 2nd-and 3rd-line therapies for non-small cell lung cancer
    Lash, Stephen
    Ye, Xin
    Reyes, Carolina
    Hille, Jeff
    Benn, Lucinda
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S428 - S428
  • [7] ACTIVITY OF THE PAN-HER TYROSINE KINASE (TK) INHIBITOR DACOMITINIB (PF-00299804) IN REFRACTORY NONADENOCARCINOMA (NON-A) NON-SMALL CELL LUNG CANCER (NSCLC) AND COMPARED WITH ERLOTINIBIN THE 2ND-/3RD-LINE SETTING
    Blackhall, F.
    Gadgeel, S. M.
    Reckamp, K. L.
    Talbot, D.
    Barrios, C.
    Krzakowski, M.
    Liang, J.
    O'Connell, J.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S60 - S60
  • [8] COMPARE ERLOTINIB WITH PEMETREXED AS 2ND/3RD LINE SETTING IN NON-SMALL CELL LUNG CANCER PATIENTS WITH BRAIN METASTASIS
    He, Y.
    Ren, S.
    Kuang, P.
    Chen, X.
    Hu, Q.
    Li, A.
    Liu, L.
    Zhou, C.
    RESPIROLOGY, 2011, 16 : 175 - 176
  • [9] ECONOMIC ANALYSIS OF ERLOTINIB, DOCETAXEL, PEMETREXED AND BEST SUPPORTIVE CARE AS 2ND OR 3RD LINE TREATMENT OF NON-SMALL CELL LUNG CANCER
    Negreiro, F.
    Pereira, C.
    Pereira, H.
    Silva, C.
    VALUE IN HEALTH, 2008, 11 (06) : A476 - A476
  • [10] A phase 1/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): Phase 1 results
    Papadimitrakopoulou, V.
    Blumenschein, G. R., Jr.
    Leighl, N. B.
    Bennouna, J.
    Soria, J. C.
    Burris, H. A., III
    Dimitrijevic, S.
    Kunz, T.
    Di Scala, L.
    Johnson, B. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345